(0.22%) 5 250.75 points
(0.19%) 39 613 points
(0.27%) 18 264 points
(0.30%) $79.50
(0.48%) $2.31
(1.47%) $2 374.70
(1.66%) $28.84
(0.91%) $999.80
(0.03%) $0.928
(-0.34%) $10.83
(-0.04%) $0.798
(-0.50%) $92.08
3.48% ¥ 3 420.00
Live Chart Being Loaded With Signals
Mizuho Medy Co.,Ltd. researches and develops, manufactures, and sells in-vitro diagnostic products and related scientific and technical information services primarily in Japan...
Stats | |
---|---|
Volumen de hoy | 173 600 |
Volumen promedio | 53 663.00 |
Capitalización de mercado | 32.57B |
EPS | ¥0 ( 2024-05-09 ) |
Last Dividend | ¥40.00 ( 2023-06-29 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 8.63 |
ATR14 | ¥3.21 (0.09%) |
Volumen Correlación
Mizuho Medy Co.,Ltd. Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Mizuho Medy Co.,Ltd. Correlación - Moneda/Commodity
Mizuho Medy Co.,Ltd. Finanzas
Annual | 2023 |
Ingresos: | ¥10.99B |
Beneficio Bruto: | ¥8.03B (73.03 %) |
EPS: | ¥396.27 |
FY | 2023 |
Ingresos: | ¥10.99B |
Beneficio Bruto: | ¥8.03B (73.03 %) |
EPS: | ¥396.27 |
FY | 2022 |
Ingresos: | ¥17.58B |
Beneficio Bruto: | ¥14.10B (80.20 %) |
EPS: | ¥822.94 |
Financial Reports:
No articles found.
Mizuho Medy Co.,Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥190.00 (N/A) |
¥0 (N/A) |
¥40.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥9.25 | 2015-12-28 |
Last Dividend | ¥40.00 | 2023-06-29 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 12 | -- |
Total Paid Out | ¥555.75 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.8 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.26 | |
Div. Directional Score | 7.27 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8174.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7552.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6762.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6101.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4812.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
4026.T | Ex Dividend Knight | 2023-10-30 | Semi-Annually | 0 | 0.00% | |
3242.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
2267.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9101.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7981.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.343 | 1.500 | 3.13 | 4.70 | [0 - 0.5] |
returnOnAssetsTTM | 0.199 | 1.200 | 3.36 | 4.03 | [0 - 0.3] |
returnOnEquityTTM | 0.262 | 1.500 | 8.20 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 7.15 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 6.38 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.82 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0511 | -1.500 | 9.15 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 41.05 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 41.05 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0618 | -1.500 | 9.75 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.735 | 1.000 | 1.089 | 1.089 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.469 | 1.000 | 2.62 | 2.62 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.404 | 1.000 | 8.87 | 8.87 | [0.2 - 2] |
assetTurnoverTTM | 0.580 | 0.800 | 9.47 | 7.57 | [0.5 - 2] |
Total Score | 10.28 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.68 | 1.000 | 9.22 | 0 | [1 - 100] |
returnOnEquityTTM | 0.262 | 2.50 | 8.84 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 41.05 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.33 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 41.05 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0356 | 1.000 | -1.611 | 0 | [0.1 - 0.5] |
Total Score | 4.26 |
Mizuho Medy Co.,Ltd.
Mizuho Medy Co.,Ltd. researches and develops, manufactures, and sells in-vitro diagnostic products and related scientific and technical information services primarily in Japan. The company provides immunoassay test products, such as influenza virus kits; RS virus and human metapneumovirus antigen test kits; streptococcus pneumoniae antigen and legionella antigen test kits; mycoplasma pneumoniae antigen test kits; adenovirus antigen test kits; rotavirus and adenovirus antigen test kits; norovirus antigen test kits; group a streptococcal antigen test kits; pregnancy test kits; ovulation test kits; and fecal occult blood test kits. It also offers gene analysis instrument; SARS-CoV-2 detection kits; and mycoplasma pneumoniae nucleic acid kits. In addition, the company engages in import and export activities. It also operates in the United States, Belgium, Finland, Netherlands, Taiwan, Thailand, etc. The company was incorporated in 1977 and is headquartered in Tosu, Japan.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico